Terms: = Uterine cancer AND CEP17 AND Treatment
2 results:
1. HER2 Genetic Intratumor Heterogeneity Is Associated With Resistance to Trastuzumab and Trastuzumab Emtansine Therapy in Recurrent High-Grade Endometrial cancer.
Shen S; Ma W; Brown D; Da Cruz Paula A; Zhou Q; Iaosonos A; Tessier-Cloutier B; Ross DS; Troso-Sandoval T; Reis-Filho JS; Abu-Rustum N; Zhang Y; Ellenson LH; Weigelt B; Makker V; Chui MH
Mod Pathol; 2023 Nov; 36(11):100299. PubMed ID: 37558129
[TBL] [Abstract] [Full Text] [Related]
2. An exploratory analysis of HER-2 amplification and overexpression in advanced endometrial carcinoma: a Gynecologic Oncology Group study.
Grushko TA; Filiaci VL; Mundt AJ; Ridderstråle K; Olopade OI; Fleming GF;
Gynecol Oncol; 2008 Jan; 108(1):3-9. PubMed ID: 17945336
[TBL] [Abstract] [Full Text] [Related]